XSAT:DANCAN (Denmark)
Â
Unit (5 Ordinary shares & 2 Wrts)
kr
0.14
-0.0040 (-2.78%)
Jan 22
Business Description
DanCann Pharma AS
ISIN : DK0063631999
Share Class Description:
XSAT:DANCAN: Unit (5 Ordinary shares & 2 Wrts)Total Employee Number:
5Compare
Compare
Traded in other countries / regions
DAN0.GermanyDANCAN.SwedenDCPXF.USA IPO Date
2020-11-12Description
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.55 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.95 | |||||
Beneish M-Score | 2.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -39.1 | |||||
3-Year EBITDA Growth Rate | 78.3 | |||||
3-Year EPS without NRI Growth Rate | 73.8 | |||||
3-Year FCF Growth Rate | 85.4 | |||||
3-Year Book Growth Rate | -80.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.07 | |||||
9-Day RSI | 24.82 | |||||
14-Day RSI | 29.77 | |||||
3-1 Month Momentum % | 150 | |||||
6-1 Month Momentum % | -47.14 | |||||
12-1 Month Momentum % | -74.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.39 | |||||
Quick Ratio | 0.39 | |||||
Cash Ratio | 0.09 | |||||
Days Inventory | 3.51 | |||||
Days Sales Outstanding | 45.89 | |||||
Days Payable | 97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -235.2 | |||||
Shareholder Yield % | -35.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -51.39 | |||||
Operating Margin % | -208.92 | |||||
Net Margin % | -214.25 | |||||
EBITDA Margin % | -161.29 | |||||
FCF Margin % | -11.4 | |||||
OCF Margin % | -11.4 | |||||
ROE % | -84.03 | |||||
ROA % | -64.32 | |||||
ROIC % | -68.91 | |||||
3-Year ROIIC % | -8.06 | |||||
ROC (Joel Greenblatt) % | -301.94 | |||||
ROCE % | -80.25 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.13 | |||||
PB Ratio | 0.08 | |||||
Price-to-Free-Cash-Flow | 140 | |||||
Price-to-Operating-Cash-Flow | 140 | |||||
EV-to-EBIT | -0.01 | |||||
EV-to-EBITDA | -0.01 | |||||
EV-to-Revenue | 0.01 | |||||
EV-to-FCF | -0.12 | |||||
Price-to-GF-Value | 0.27 | |||||
Earnings Yield (Greenblatt) % | -10000 | |||||
FCF Yield % | -89.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DanCann Pharma AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 4.394 | ||
| EPS (TTM) (kr) | -2.679 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.27 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 113.89 | ||
| 14-Day RSI | 29.77 | ||
| 14-Day ATR (kr) | 0.086209 | ||
| 20-Day SMA (kr) | 0.3376 | ||
| 12-1 Month Momentum % | -74.77 | ||
| 52-Week Range (kr) | 0.1076 - 2.2 | ||
| Shares Outstanding (Mil) | 3.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DanCann Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DanCann Pharma AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-27 18:00 | In 88 days | ||
| Second quarter earnings results for 2026 | 2026-08-25 18:00 | In 25 days | ||
| First quarter earnings results for 2026 | 2026-05-22 18:00 | 0.14 (-15.29%) | ||
| General meeting for 2026 | 2026-04-24 09:00 | 0.14 (-15.29%) | ||
| Annual report for 2025 | 2026-04-03 | 0.14 (-15.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 0.14 (-15.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 0.14 (-15.29%) | ||
| Third quarter earnings results for 2025 | 2025-10-27 18:00 | 0.27 (+20.91%) | ||
| Second quarter earnings results for 2025 | 2025-08-25 18:00 | 0.95 (+4.40%) | ||
| First quarter earnings results for 2025 | 2025-05-23 18:00 | 1.64 (+4.46%) |
Show
Entries
DanCann Pharma AS Frequently Asked Questions
What is DanCann Pharma AS(XSAT:DANCAN)'s stock price today?
The current price of XSAT:DANCAN is kr0.14. The 52 week high of XSAT:DANCAN is kr2.20 and 52 week low is kr0.11.
When is next earnings date of DanCann Pharma AS(XSAT:DANCAN)?
The next earnings date of DanCann Pharma AS(XSAT:DANCAN) is 2026-08-25 Est..
Does DanCann Pharma AS(XSAT:DANCAN) pay dividends? If so, how much?
DanCann Pharma AS(XSAT:DANCAN) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| DanCann Pharma A/S publishes Q1-2023 report | 2023-05-31 | ||
| DanCann Pharma A/S publishes Annual Report 2022 | 2023-05-12 | ||
| DanCann Pharma A/S publishes Q4-2022 report | 2023-02-28 |
Articles on DanCann Pharma AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers